Liraglutide: what the Saxenda label supports

The February 2026 Saxenda label describes long-term weight reduction with diet and activity in specified adults and certain adolescents aged 12 or older who also meet a weight threshold. FDA’s pediatric approval announcement explains the adolescent extension. A clinician must determine whether an individual meets current label criteria and whether the product fits their medical history. DailyMed: Saxenda current label FDA: Saxenda pediatric indication

The label’s clinical studies section reports controlled trials of Saxenda in defined populations. Those results describe group averages and specific endpoints, not guaranteed outcomes or evidence for an unrelated peptide. NIDDK lists liraglutide in the context of approved weight-management medicines and emphasizes broader lifestyle care. Ask which study population resembles you and what outcome the clinician plans to follow. DailyMed: Saxenda current label NIDDK: Prescription medicines for weight management

The label has limitations on coadministration with other liraglutide products or another GLP-1 receptor agonist and includes important warnings and adverse reactions. A clinician should review the complete current label and other medicines; this article cannot set a dosing plan. The same ingredient may appear in a different product with its own indication and instructions. DailyMed: Saxenda current label

FDA’s compounding Q&A explains that compounded drugs are not FDA-approved. FDA’s April 2026 policy list includes a 503B bulk-list proposal involving liraglutide, which should not be presented as a final rule or as approval of a compounded copy. Ask for the exact finished drug and current legal basis if a compounded option is discussed. Verify the proposed product and local care arrangement directly with the prescribing service. FDA: Human drug compounding policies and rules FDA: Compounding and the FDA Q&A

The adult and adolescent label populations have distinct criteria, and the adolescent indication includes a body-weight threshold. A clinician should assess age, diagnosis, growth, other conditions, and the current label instead of using an adult internet checklist. FDA’s pediatric approval notice gives context for why a specific supplement was reviewed; it does not make every pediatric use appropriate. FDA: Saxenda pediatric indication

Ask how response will be measured, what adverse effects require contact, and how long the clinician expects to reassess. Nutrition and activity remain part of the labeled treatment context, but the plan must be individualized. NIDDK explains that weight-management medicines complement broader care and that eligibility does not guarantee a prescription. If the medication is unaffordable or difficult to obtain, discuss that early so the plan is sustainable. NIDDK: Prescription medicines for weight management